Bicara Therapeutics Inc. SEC filings BCAX
Bicara Therapeutics Inc. has 263 filings in SEC EDGAR's recent list, going back to Jun 10, 2024. Its latest annual report, Form ARS, was filed on Apr 27, 2026 for the period ended Apr 21, 2026. The latest quarterly report (Form 10-Q) was filed on Aug 11, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Aug 25, 2026 (material agreement). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Material agreement
|
Aug 25, 2026 | Aug 21, 2026 |
| S-8 | Employee stock plan registration | Aug 11, 2026 | — |
| 10-Q | Quarterly report | Aug 11, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 11, 2026 | Aug 11, 2026 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Jul 28, 2026 | Jul 23, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 10, 2026 | Jun 9, 2026 |
| 8-K |
Current report
Other events
|
May 21, 2026 | May 21, 2026 |
| 10-Q | Quarterly report | May 11, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Results of operations
|
May 11, 2026 | May 11, 2026 |
| ARS | Annual report to shareholders | Apr 27, 2026 | Apr 21, 2026 |
| DEFA14A | Additional proxy material | Apr 27, 2026 | — |
| DEF 14A | Proxy statement | Apr 27, 2026 | Apr 21, 2026 |
| S-8 | Employee stock plan registration | Mar 31, 2026 | — |
| 10-K | Annual report | Mar 30, 2026 | Dec 31, 2025 |
| 8-K |
Current report
Results of operations
|
Mar 30, 2026 | Mar 30, 2026 |
| 8-K |
Current report
Material agreement, Results of operations
|
Feb 26, 2026 | Feb 24, 2026 |
| 424B5 | Prospectus supplement | Feb 26, 2026 | — |
| FWP | Free writing prospectus | Feb 25, 2026 | — |
| 424B5 | Prospectus supplement | Feb 24, 2026 | — |
| 8-K |
Current report
Other events
|
Feb 19, 2026 | Feb 19, 2026 |
| 8-K |
Current report
Other events
|
Jan 12, 2026 | Jan 12, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Dec 8, 2025 | Dec 6, 2025 |
| EFFECT | Filing | Nov 26, 2025 | — |
| 424B5 | Prospectus supplement | Nov 26, 2025 | — |
| CORRESP | Letter to the SEC | Nov 24, 2025 | — |
| 10-Q | Quarterly report | Nov 10, 2025 | Sep 30, 2025 |
| 8-K |
Current report
Results of operations
|
Nov 10, 2025 | Nov 10, 2025 |
| S-3 | Shelf registration | Oct 3, 2025 | — |
| 10-Q | Quarterly report | Aug 12, 2025 | Jun 30, 2025 |
| 8-K |
Current report
Results of operations
|
Aug 12, 2025 | Aug 12, 2025 |
| 8-K |
Current report
Shareholder vote results
|
Jun 12, 2025 | Jun 9, 2025 |
| 8-K |
Current report
Material agreement
|
Jun 6, 2025 | Jun 2, 2025 |
| 10-Q | Quarterly report | May 13, 2025 | Mar 31, 2025 |
| 8-K |
Current report
Results of operations
|
May 13, 2025 | May 13, 2025 |
| ARS | Annual report to shareholders | Apr 25, 2025 | Dec 31, 2024 |
| DEFA14A | Additional proxy material | Apr 25, 2025 | — |
| DEF 14A | Proxy statement | Apr 25, 2025 | Jun 9, 2025 |
| S-8 | Employee stock plan registration | Mar 28, 2025 | — |
| 10-K | Annual report | Mar 27, 2025 | Dec 31, 2024 |
| 8-K |
Current report
Results of operations
|
Mar 27, 2025 | Mar 27, 2025 |
| 8-K |
Current report
Regulation FD disclosure
|
Jan 13, 2025 | Jan 13, 2025 |
| 10-Q | Quarterly report | Nov 12, 2024 | Sep 30, 2024 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Nov 12, 2024 | Nov 12, 2024 |
| 8-K |
Current report
Bylaw or fiscal year change
|
Sep 16, 2024 | Sep 12, 2024 |
| SEC STAFF LETTER | Filing | Sep 13, 2024 | — |
| S-8 | Employee stock plan registration | Sep 13, 2024 | — |
| 424B4 | Prospectus | Sep 13, 2024 | — |
| EFFECT | Filing | Sep 12, 2024 | — |
| S-1MEF | Filing | Sep 12, 2024 | — |
| CERT | Filing | Sep 12, 2024 | — |
| S-1/A | Amended registration statement | Sep 11, 2024 | — |
| 8-A12B | Filing | Sep 10, 2024 | — |
| CORRESP | Letter to the SEC | Sep 10, 2024 | — |
| CORRESP | Letter to the SEC | Sep 10, 2024 | — |
| S-1/A | Amended registration statement | Sep 6, 2024 | — |
| CORRESP | Letter to the SEC | Sep 3, 2024 | — |
| S-1/A | Amended registration statement | Sep 3, 2024 | — |
| UPLOAD | Letter from the SEC | Aug 29, 2024 | — |
| CORRESP | Letter to the SEC | Aug 27, 2024 | — |
| CORRESP | Letter to the SEC | Aug 22, 2024 | — |
| S-1 | Registration statement | Aug 22, 2024 | — |
| UPLOAD | Letter from the SEC | Aug 6, 2024 | — |
| DRS/A | Filing | Jul 22, 2024 | — |
| DRSLTR | Filing | Jul 22, 2024 | — |
| SEC STAFF LETTER | Filing | Jul 8, 2024 | — |
| UPLOAD | Letter from the SEC | Jul 5, 2024 | — |
| DRS | Filing | Jun 10, 2024 | — |
Showing 67 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- BCAX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Boston, MA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 2023658
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.